Exact Therapeutics AS (OSL:EXTX) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Exact Therapeutics AS's annualized Gross Profit for the quarter that ended in Dec. 2023 was kr0.00 Mil. Exact Therapeutics AS's average Total Assets over the quarter that ended in Dec. 2023 was kr57.07 Mil. Therefore, Exact Therapeutics AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Exact Therapeutics AS Gross-Profit-to-Asset % Historical Data

The historical data trend for Exact Therapeutics AS's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS Gross-Profit-to-Asset % Chart

Exact Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

Exact Therapeutics AS Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Exact Therapeutics AS's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Exact Therapeutics AS's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Therapeutics AS's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Exact Therapeutics AS's Gross-Profit-to-Asset % falls into.

Exact Therapeutics AS Gross-Profit-to-Asset % Calculation

Exact Therapeutics AS's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (82.508	+	61.319)	/ 2 )
	=	0	/	71.9135
	=	0.00 %

Exact Therapeutics AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (52.819	+	61.319)	/ 2 )
	=	0	/	57.069
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Exact Therapeutics AS Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Therapeutics AS (OSL:EXTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ostre Aker vei 19, Oslo, NOR, 0581

Website

https://www.exact-tx.com

Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines